PRTC - PureTech Health PLC

PRTC - PureTech Health PLC

https://www.puretechhealth.com

Recent News

Powered by Alpha Vantage

PureTech Health Cash Runway Extended

Motley Fool • 1 week, 5 days ago • score: 0.16

PureTech Health ( NASDAQ:PRTC ) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in consolidated operating expenses to $50 million from $66.7 million year-over-year in the first ...

PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients - PureTech Health ( NASDAQ:PRTC )

Benzinga • 8 months, 4 weeks ago • score: 0.13

PureTech Health plc PRTC stock is up on Monday, after the company announced results from ELEVATE IPF Phase 2b trial of deupirfenidone ( LYT-100 ) for idiopathic pulmonary fibrosis ( IPF ) . The trial evaluated deupirfenidone at two doses three times a day ( TID ) over 26 weeks in IPF ...

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Boeing ( NYSE:BA )

Benzinga • 1 year ago • score: -0.08

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 100 points on Tuesday. Shares of Dyne Therapeutics, Inc.

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday - Galapagos ( NASDAQ:GLPG )

Benzinga • 1 year ago

U.S. stocks were mostly higher, with the Dow Jones index gaining around 150 points on Monday. Shares of Galapagos NV GLPG rose sharply during Monday's session after Ecor1 Capital reported a 9.9% stake in the company. Galapagos shares jumped 10% to $28.47 on Monday.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.

52W High

$24.99

52W Low

$13.30

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.82

Valuation

Attractive

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

9.55

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

2.10

EV/Revenue (<3 favorable)

12.89

P/S (TTM) (<3 favorable)

61.38

P/B (<3 favorable)

1.04

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

1.47%

Shares Outstanding

24,168,400

Float

165,660,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

6,391,000

Gross Profit (TTM)

-48,809,000

EPS (TTM)

1.70

Profit Margin (>10% good)

7.93%

Operating Margin (TTM) (higher better)

-25.90%

ROE (TTM) (>15% strong)

0.09%

EPS YoY (Quarterly) (>10% good)

0.62

Revenue YoY (Quarterly) (>8% good)

5.43

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—